Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
Pelican AI: +34,75% in Frankfurt! Ist das erst der Anfang einer großen Kursrallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
MB

WKN: A3EQVV | ISIN: CA57384M1077 | Ticker:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MARVEL BIOSCIENCES CORP Chart 1 Jahr
5-Tage-Chart
MARVEL BIOSCIENCES CORP 5-Tage-Chart

Aktuelle News zur MARVEL BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiMarvel Biosciences Corp: Marvel Biosciences talks Shank 3 preliminary data2
DiMarvel Biosciences Corp.: Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours2
DiMarvel Biosciences shares preliminary MB-204 autism mouse-study data-
19.10.Marvel Biosciences Corp: Marvel Biosciences picks CMAX for MB-204 phase 1 trial1
19.10.Marvel Biosciences Corp.: Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site1
09.10.Marvel Biosciences Corp: Marvel Biosciences 10,654,298-share private placement1
MARVEL BIOSCIENCES Aktie jetzt für 0€ handeln
08.10.Marvel Biosciences Corp.: Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model192CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or...
► Artikel lesen
06.10.Marvel Biosciences Corp: Marvel Biosciences signs LOI with Novatech for trial3
06.10.Marvel Biosciences Corp.: Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update203CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or...
► Artikel lesen
30.09.Marvel Biosciences closes private placement for C$1.6M3
30.09.Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million660Calgary, Alberta--(Newsfile Corp. - September 29, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August...
► Artikel lesen
17.09.Marvel Biosciences announces non-brokered private placement for up to $3M1
17.09.Marvel Biosciences plant Privatplatzierung von bis zu 3 Mio. C$1
17.09.Marvel Biosciences plans private placement of up to C$3M1
17.09.Marvel Biosciences Corp.: Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million631Calgary, Alberta--(Newsfile Corp. - September 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August...
► Artikel lesen
10.09.Marvel Biosciences Corp: Marvel Biosciences extends placement to Sept. 141
09.09.Marvel Biosciences gets approval to extend private placement deadline1
09.09.Marvel Biosciences Corp.: Marvel Biosciences Announces Extension to Closing Date of Private Placement514Calgary, Alberta--(Newsfile Corp. - September 9, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it has received approval from the TSX Venture...
► Artikel lesen
20.08.Marvel Biosciences Corp: Marvel Biosciences expands financing to Quebec2
19.08.Marvel Biosciences Corp.: Marvel Biosciences Expands Private Placement to Quebec555Calgary, Alberta--(Newsfile Corp. - August 19, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it is expanding its previously announced private...
► Artikel lesen
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1